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We thank Dr. Sise and co-workers very much for their
letter and interest in our recent publication.1 We
appreciate them sharing their stratified analysis among
the subset of their patients with chronic kidney disease
from their provocative study.2
We would like to make a clarification regarding the
statement ‘it is not surprising that Hsu et al. found that
serum creatinine cannot distinguish between natural pro-
gression of CKD and acute-on-chronic disease.’ What we
had said was that ‘Among patients with very advanced
chronic kidney disease, it may be difficult to distinguish
between the final stages of progression to end-stage renal
disease from potentially reversible acute-on chronic renal
failure so the very high odds ratio observed among
those with estimated GFR of o15 ml per min per 1.73 m2
must be interpreted with caution.’1 Using direct medical
records review of a random sample of 100 patients with
baseline estimated GFR o45 ml/min per 1.73 m2, we
demonstrated that we were able to identify accurately cases
of acute-on-chronic kidney disease. As described in the
paper, a board-certified nephrologist confirmed that 100% of
the time, our algorithm captured true cases of acute renal
failure/acute kidney injury and did not mistakenly include
cases of progression of chronic kidney disease. The etiology
of these 100 cases of acute on chronic renal failure are
shown below and are comparable to that reported in prior
studies.3
We agree completely that neutrophil gelatinase-
associated lipocalin and other biomarkers are an exciting
area of research in acute kidney injury. Currently these
biomarkers are being validated against ‘gold standard’
definitions of acute kidney injury as determined by
changes in serum creatinine.2,4,5 Our understanding of
the epidemiology of acute kidney injury and the role of
biomarkers should be greatly enhanced with the antici-
pated launch of the NIH-NIDDK sponsored study of the
natural history of acute kidney injury (http://grants.
nih.gov/grants/guide/rfa-files/RFA-DK-07-009.html).
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To the Editor: Ahmed et al1 investigate a facet of
postmenopausal hormone therapy (HT) hereunto unad-
dressed by the Women’s Health Initiative, but their
epidemiologic approach raises several questions.
The authors chose age 66 as the minimal age for
enrollment (mean age 470), and subjects were largely
plagued by various chronic ailments and renal compromise
(estimated glomerular filtration rate o90 ml/min per
1.73 m2). As younger (o age 60) women with normal renal
function account for the overwhelming majority of HT
utilization, why did the investigators select a markedly
Etiology
Decreased renal perfusion (including volume contraction,
congestive heart failure, hypotension, cardiac arrest)
76
Medication related 0
Radiocontrast media 6
Postoperative 6
Sepsis 21
Others 6
Total exceeds 100 as some cases had more than one contributing etiology
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older population with multiple underlying chronic condi-
tions? As a laboratory and commercial insurance database
was tapped, the authors should disclose whether the
null hypothesis was met in women o age 66. Recent
subgroup analysis of the Women’s Health Initiative data
suggests that estrogen is cardioprotective2 and neuroprotec-
tive3 on healthy tissues of newly menopausal women, and
data obtained from women distant from menopause should
not be extrapolated to younger menopausal women.4 Any
temptation to generalize the findings of Ahmed et al, to
newly menopausal women with normal renal function should
be avoided.
Systemic HT is indicated for women suffering menopausal
symptoms (primarily hot flushes), a condition decidedly
uncommon in women distant from menopause. Nothing
about menopausal symptomatology is disclosed in this study,
and hence, the number of subjects who were truly
appropriate candidates for HT cannot be determined. HT
exposure was ascertained if subjects filled one prescription
over the entire study interval (approximately 2 years). It is
likely that many subjects did not take HT over the entire
study interval (dropout rates in the combined HT arm of the
Women’s Health Initiative exceeded 40%). Without direct
patient contact, compliance could not be monitored, and the
cumulative HT dose calculation in Figure 1 can only be
viewed as speculative.
Conjugated estrogens administered at 0.625 mg daily is
considered excessive (with potential toxicity) for most older
women with diminished muscle mass and adipose volume.5
A lower dosage would be more appropriate. Adverse effects
associated with HT are largely dose and duration dependent.
I am concerned that the exposure studied does not reflect
contemporary clinical practice.
The control and study groups (Table 1) are dissimilar
across multiple parameters, yet the authors did not control
for non-HT drug exposure (nonsteroidal anti-inflammatory
drugs use was disproportionately higher in the estrogen arm).
This may be an important confounder and could account for
the small albeit statistically significant estimated glomerular
filtration rate differences. Analysis of women free of
medications known to influence renal function would have
been more instructive.
This study illustrates many limitations associated with post
hoc exploratory analysis. I agree that a randomized trial is
needed, but it must focus on a well-defined younger and
relatively symptomatic menopausal population treated with
appropriate dosages of hormones.
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Table 1 | Baseline subject characteristics by categorical HT use (N=5845)a
Characteristic No use (n=4386) Estrogen only (n=1083) Progestin only (n=40) Both (n=336) P-valueb
Age, years 77.5±7.2 75.1±6.1 74.4±5.5 72.8±5.2 o0.0001
eGFR, ml/min per 1.73 m2 62.3±17.1 65.4±15.4 63.0±16.0 67.6±15.4 o0.0001
Diabetes (%) 16.6 10.6 22.5 8.6 o0.0001
Chronic Disease Score 2458 (1789, 3447) 2621 (1853, 3556) 2471 (1868, 3589) 2217 (1555, 3050) 0.0001
Drug use in prior year (%)
ACE-I/ARB 41.9 40.7 45.0 36.3 0.2
b-Blocker 20.8 24.8 35.0 19.9 0.005
Lipid lowering 21.1 23.0 35.0 21.7 0.10
Diuretics 41.7 46.8 52.5 36.0 0.0008
NSAIDs 35.8 45.3 35.0 37.8 o0.0001
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; HT, hormone therapy; ; NSAID, nonsteroidal
anti-inflammatory drug.
aAge and eGFR expressed as mean±s.d.; Chronic Disease Score expressed as median and interquartile range.
bP-value calculated by ANOVA for age and eGFR, w2-test for categorical variables, and Kruskal–Wallis test for Chronic Disease Score.
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Figure 1 | Cumulative estrogen exposure versus predicted
decline in mean eGFR.
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